VTCN1 and ovarian neoplasm: ADCs targeting B7-H3 and B7-H4 offer a novel mechanism to selectively deliver cytotoxic agents to ovarian tumors, with the potential to improve therapeutic efficacy while minimizing off-target toxicity.